These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 22177566)
1. Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia. Cocco C; Pistoia V; Airoldi I Crit Rev Oncol Hematol; 2012 Sep; 83(3):310-8. PubMed ID: 22177566 [TBL] [Abstract][Full Text] [Related]
2. Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Nagai H; Oniki S; Fujiwara S; Yoshimoto T; Nishigori C Immunotherapy; 2010 Sep; 2(5):697-709. PubMed ID: 20874653 [TBL] [Abstract][Full Text] [Related]
3. Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. Lo CH; Chang CM; Tang SW; Pan WY; Fang CC; Chen Y; Wu PY; Chen KY; Ma HI; Xiao X; Tao MH J Gene Med; 2010 May; 12(5):423-34. PubMed ID: 20440753 [TBL] [Abstract][Full Text] [Related]
4. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173 [No Abstract] [Full Text] [Related]
5. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Cocco C; Canale S; Frasson C; Di Carlo E; Ognio E; Ribatti D; Prigione I; Basso G; Airoldi I Blood; 2010 Nov; 116(19):3887-98. PubMed ID: 20671120 [TBL] [Abstract][Full Text] [Related]
6. Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia. Cocco C; Airoldi I Cytokine Growth Factor Rev; 2011 Jun; 22(3):149-56. PubMed ID: 21764355 [TBL] [Abstract][Full Text] [Related]
13. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418 [TBL] [Abstract][Full Text] [Related]
14. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Gee K; Guzzo C; Che Mat NF; Ma W; Kumar A Inflamm Allergy Drug Targets; 2009 Mar; 8(1):40-52. PubMed ID: 19275692 [TBL] [Abstract][Full Text] [Related]
15. Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab). Kraal K; Schalij-Delfos N; van Buchem M; Egeler M; Ball L Haematologica; 2005 Nov; 90 Suppl():ECR24. PubMed ID: 16266915 [TBL] [Abstract][Full Text] [Related]
16. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465 [No Abstract] [Full Text] [Related]
17. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Duell J; Bargou RC; Holland C; Benjamin JE; Klinger M; Litzow MR Leukemia; 2018 Feb; 32(2):562-565. PubMed ID: 28990581 [No Abstract] [Full Text] [Related]
18. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Liu Y; Chen X; Han W; Zhang Y Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276 [TBL] [Abstract][Full Text] [Related]
19. Influence of glycosylation on IL-12 family cytokine biogenesis and function. Bohnacker S; Hildenbrand K; Aschenbrenner I; Müller SI; Bieren JE; Feige MJ Mol Immunol; 2020 Oct; 126():120-128. PubMed ID: 32823236 [TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]